ArticleThoracic cancer2019

First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China.

Qing Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.